SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative
3D Bioprinting Market Size, Share, Revenue, Trends And Drivers For 2024-2033 einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO – Free Report) in a report released on Monday. The brokerage issued a sell rating on the medical research company’s stock. Organovo Price Performance Organovo stock opened at $1.09 on Monday. The company has a market cap of $9.50 million, a PE ratio of -0.51 and a […]
StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO – Free Report) in a research note released on Sunday. The brokerage issued a sell rating on the medical research company’s stock. Organovo Stock Performance Shares of NASDAQ:ONVO opened at $1.17 on Friday. The company’s 50-day moving average is $1.26 and its 200 day moving average is […]
Stock analysts at StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO – Get Free Report) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the medical research company’s stock. Organovo Stock Performance Shares of ONVO opened at $1.08 on Friday. The stock has a market cap of $9.42 million, […]